Immunome(NASDAQ) IMNM

Immunome, Inc. helps doctors treat cancer with targeted medicines. These drugs destroy tumors without hurting healthy cells. The treatments help people fighting rare or advanced cancers.

Targeting Cancer With Precision

• Varegacestat: Oral medicine for desmoid tumors awaiting a federal approval decision by April 2027.
• IM-1021: Antibody-drug conjugate, which pairs an antibody with a drug to target B-cell lymphomas.
• IM-3050: Radioligand therapy designed to deliver radioactive material directly to cancer-associated cells.
• IM-1340: Targeted therapy for lung and prostate tumors currently in early development stages.

Recent Steps Forward

• Acquired the lead drug candidate varegacestat from Ayala Pharmaceuticals in March 2024.
• Submitted a new drug application to the U.S. Food and Drug Administration for varegacestat in April 2026.
• Dosed the first patient in a Phase 1 clinical trial for the IM-1617 program in June 2026.
• Began human testing for the radioactive therapy IM-3050 in its first patient in July 2026.

How the Science Works

Immunome uses specialized technology to build antibody-drug conjugates. These medicines link cancer-killing drugs to targeted antibodies to reach tumors while protecting healthy tissue. The company employs a development team with experience creating multiple approved oncology therapies.

The Financial Scorecard

• Net loss was $73.1 million for the three months ended June 30, 2026.
• Research and development spending reached $59.9 million for the three months ended June 30, 2026.
• Cash and cash equivalents were $217.7 million as of June 30, 2026.
• Marketable securities totaled $302.3 million as of June 30, 2026.
• Market cap was $2.4 billion in Q2 2026, up 196.6% year over year.

Bottom Line

Immunome has grown into a clinical-stage biotechnology company with several active programs for treating tumors. Its focus on targeted delivery methods and late-stage assets drives its current effort to improve cancer care.